DSGN
Design Therapeutics Inc

377
Loading...
Loading...
News
all
press releases
Biotech stocks jump as Makary outlines FDA vision, RBC comments
Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.
investing.com·5mo ago
News Placeholder
More News
News Placeholder
Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in Stock
Design Therapeutics, Inc. (NASDAQ:DSGN Get Free Report) Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The shares were...
Ticker Report·1y ago
News Placeholder
Design Therapeutics (DSGN, $3.9) RSI Indicator left the overbought zone on March 27, 2024
This is a signal that DSGN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
Design Therapeutics (DSGN, $3.58) RSI Indicator left the overbought zone on March 26, 2024
This is a signal that DSGN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
Equities Analysts Set Expectations for Design Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:DSGN)
Design Therapeutics, Inc. (NASDAQ:DSGN Free Report) Analysts at Leerink Partnrs boosted their Q1 2024 EPS estimates for shares of Design Therapeutics in a research report issued on...
Zolmax·1y ago
News Placeholder
Design Therapeutics (DSGN, $3.25) RSI Indicator left the overbought zone on March 21, 2024
This is a signal that DSGN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Hold" from Brokerages
Design Therapeutics, Inc. (NASDAQ:DSGN Get Free Report) has been given a consensus recommendation of Hold by the seven research firms that are currently covering the company...
Ticker Report·1y ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Receives "Neutral" Rating from Wedbush
Design Therapeutics (NASDAQ:DSGN Get Free Report)s stock had its neutral rating reissued by Wedbush in a report issued on Wednesday, Benzinga reports. They presently have...
Ticker Report·1y ago
News Placeholder
Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress
Advancements in GeneTAC Platform and Strong Cash Position HighlightedRelated Stocks: DSGN...
GuruFocus·1y ago
News Placeholder
Design Therapeutics reports Q4 EPS (21c), consensus (31c)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago

Latest DSGN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.